State-of-the-art <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>γ</mml:mi></mml:math>-ray assay of <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mmultiscripts><mml:mi mathvariant="normal">Y</mml:mi><mml:mprescripts/><mml:none/><mml:mn>86</mml:mn></mml:mmultiscripts></mml:math> for medical imaging
A. Gula, E. A. McCutchan, C. J. Lister, J. P. Greene, S. Zhu, Paul A. Ellison, Robert J. Nickles, M. P. Carpenter, Suzanne V. Smith, A. A. Sonzogni
Abstract
An emerging direction in nuclear medicine is the coupling of a therapeutic isotope with an imaging isotope to form a so-called theranostic pair, which allows one to quantitatively track and image the delivery of the therapeutic isotope. $^{90}\mathrm{Y}$ is used in several therapy applications and a convenient candidate imaging partner is the positron emitter $^{86}\mathrm{Y}$. A 27.6 MBq source of $^{86}\mathrm{Y}$ was produced at the University of Wisconsin and assayed with the Gammasphere array at Argonne National Laboratory. Over 200 $\ensuremath{\gamma}$-ray transitions were identified, more than double that which was previously known. The positron emission probability inferred from the present level scheme leads to 27.9(12)%, an important $(\ensuremath{\approx}14%)$ reduction with respect to the previously recommended value.